If artificial intelligence (AI) in your manufacturing environment has felt like a gray area, FDA and EMA have now given teams a clearer set of guardrails.
On January 14, 2026, the FDA and the European Medicines Agency (EMA) jointly released the Guiding Principles of Good AI Practice in Drug Development. It’s the first unified transatlantic framework explicitly addressing AI across the full medicines lifecycle — early research, clinical trials, manufacturing, and post-marketing safety. That final phase is the one your quality and maintenance teams need to sit with.
GxP is the umbrella term for good practice regulations across drug development; GMP and cGMP refer specifically to the manufacturing subset.
Ten principles. No prescriptive requirements. And a very clear direction of travel for every team running AI-embedded systems in current good manufacturing practice (cGMP) environments — pharmaceutical, biotech, and contract manufacturers alike.
This guidance doesn’t restrict innovation. It defines the expectations for responsible use. And if your organization hasn’t already started building an answer to the question — where is AI touching our GMP decisions? — that work starts now.
The era of treating AI as a pilot, a dashboard feature, or an IT experiment is over. FDA and EMA have established AI as subject to the same quality, safety, and reliability expectations as any other system used to generate or analyze evidence in drug development — including manufacturing.
That framing has direct consequences for how you govern AI in GMP environments. It is no longer sufficient to say “the human makes the final decision.” It is no longer acceptable to deploy an AI tool without a defined context of use, documented risk assessment, or lifecycle monitoring plan.
The principles call for a risk-based approach where validation effort scales with model risk and patient impact. They require data governance documentation equivalent to what regulators already expect for good practice (GxP) processes. And they require lifecycle monitoring that treats model performance drift the way you’d treat equipment drift: as a scheduled, documented activity with defined triggers.
These principles sit alongside a maturing regulatory architecture. The FDA finalized its Computer Software Assurance (CSA) guidance in September 2025 and updated it in February 2026. The latest version explicitly brings AI and machine learning tools into scope for risk-based assurance. For medical device manufacturers, CSA is the parallel framework — quality management system (QMS) software assurance applies wherever AI influences regulated production or quality decisions. The European Commission’s draft EU Annex 22 — the first GMP-specific AI guideline in the EU — went through public consultation in 2025. It restricts critical GMP applications to static, deterministic models. The International Society for Pharmaceutical Engineering (ISPE) published its GAMP® (Good Automated Manufacturing Practice) Guide for AI in GxP-Regulated Systems in July 2025. It extends GAMP 5 with a validation lifecycle framework specific to AI.
Together, these documents share a single thesis: AI outputs that influence GMP decisions must meet the same discipline as any other regulated system.
This is where the conversation gets specific. Maintenance decisions in GMP environments aren’t administrative ones. When AI output is used to justify continued operation of a critical asset, that output becomes evidence in a regulatory record. The FDA’s discussion paper on AI in pharmaceutical manufacturing specifically names “smart monitoring and maintenance” and “process monitoring and fault detection” as relevant use cases.
Four operational implications follow directly from the principles.
| Implication | Relevant Principles | What Teams Need |
|---|---|---|
| Context of use must be explicit | Principle 4 (Clear Context of Use); also Principle 10 (Clear, Essential Information) | Written context-of-use statement for every AI application |
| Risk-based validation is not optional | Principle 2 (Risk-Based Approach); Principle 8 (Risk-Based Performance Assessment) | Risk-tiered validation aligned to model influence and decision consequence |
| Data governance is the hidden risk | Principle 6 (Data Governance and Documentation) | Documented data lineage, preprocessing controls, ALCOA+ compliance |
| Lifecycle monitoring is the new normal | Principle 9 (Lifecycle Management) | Scheduled drift monitoring, documented revalidation triggers, change control integration |
Source: FDA/EMA Guiding Principles of Good AI Practice in Drug Development, January 2026
The principles require a well-defined context of use for every AI application: what decisions it influences, what decisions it does not, whether it is advisory or automated, and how outputs flow into GMP actions.
This distinction carries real compliance weight:
“AI recommends calibration interval adjustments for non-critical assets, reviewed and approved by the Metrology Manager.”
is a fundamentally different system than:
“AI autonomously modifies preventive maintenance (PM) schedules.”
The first is advisory with human review as a formal control. The second is automated. Both may be appropriate — but they require different validation approaches, different standard operating procedure (SOP) structures, and different monitoring cadences. Without a documented context of use, neither is defensible in an inspection.
The practical implication: every AI tool currently operating in your computerized maintenance management system (CMMS) needs a context-of-use statement on file before it becomes audit evidence.
The principles emphasize proportional validation based on model risk and decision consequence. In GMP operations, that framework generally resolves into three tiers:
One critical caution from the principles framework: a “human in the loop” is not automatically a risk reduction. Consider a reviewer signing off 200 work orders per hour, or scanning sensor patterns across 40 assets at once. They can’t realistically verify each AI output under production conditions. The effective model influence is high regardless of how the workflow is drawn. Teams should be prepared to explain actual human verification capacity — not just nominal workflow structure.
A second discipline follows from the same logic: AI systems in GMP environments must default to caution. A model should not act — or even recommend action — based on an output being “probably okay.” Where uncertainty exists, flag for human review rather than proceed silently. This bias toward caution is essential anywhere model output could influence product quality, batch disposition, or asset criticality decisions. Build the bias in deliberately. Document it in the context of use.
If your asset data is inconsistent, incomplete, or poorly structured, AI amplifies that weakness. The principles require traceable, verifiable documentation of data source provenance, processing steps, and analytical decisions — consistent with existing GxP requirements.
Be prepared to explain where data comes from, how it was processed, and how the model was tested for its intended purpose. That means regulators are evaluating data lineage — not just model outputs.
For maintenance and calibration environments, the highest-probability audit exposures cluster around three gaps:
Inability to reconstruct why the model produced a specific output. Missing metadata, absent version control, unlogged preprocessing steps. “The model said so” is not a control; it’s a documentation failure.
Third-party opacity. A vendor who cannot provide training data documentation, model version history, or performance validation records creates audit exposure for your facility. Proposed revisions to EU Annex 11, released for stakeholder consultation in 2025, are expected to strengthen supplier oversight and documentation accessibility when regulated users rely on vendors.
Uncontrolled data changes. Silent relabeling, sensor calibration shifts that alter input distributions, or well-intentioned data cleanup in training sets. These are AI-specific variants of the classic data integrity problems FDA already cites under 21 CFR 211.68(b).
The operational strategy: treat your AI training data the way you treat raw materials. Document the source. Verify the quality. Control the inputs. Your CMMS structured data model is either an asset in this context — or the first thing a reviewer questions.
The principles call for scheduled monitoring and periodic re-evaluation of AI systems to address performance drift. This is the requirement that catches most organizations off guard — not because it’s unreasonable, but because it’s unfamiliar.
Drift is what happens when the world changes and the model doesn’t know it:
A model performing well at installation can degrade quietly for months before producing a bad recommendation. Without a defined monitoring cadence, you won’t know until an auditor finds the gap — or until the recommendation causes a problem.
Monitoring must be scheduled, documented, and risk-based. Drift triggers need defined thresholds. Revalidation criteria need to be written down before a drift event occurs, not after. Any model update requires change control documentation.
The direct parallel: you wouldn’t run a critical instrument past its calibration interval without documentation. AI is not a “set it and forget it” tool in GxP.
Here’s what’s already happening in GMP facilities — in many cases without formal approval:
No defined context of use. No validation. No documentation.
The principles do not prohibit AI. They prohibit unmanaged AI. That’s a meaningful distinction. It separates organizations using these tools to strengthen compliance from those creating audit exposure without realizing it.
As EMA characterized the initiative, the principles are designed to “underpin future AI guidance” across jurisdictions. Organizations inventorying their AI use cases now — and bringing them inside a governed framework — will have a meaningful head start. These principles will likely become the template for binding requirements.
The question is not whether your team is using AI. The question is whether that use is documented, risk-tiered, and governed.
Before AI use in your facility becomes an inspection finding, here’s where to start:
Inventory your AI use cases. Include informal tools, third-party applications with embedded AI features, and any external platforms where teams are analyzing GMP data. If it influences a GMP decision — or produces output ending up in a compliance record — it belongs on this list.
Define context of use for each tool. What decisions does it influence? What decisions does it not? Is it advisory or automated? Document it now, before the next audit cycle.
Assign a risk tier. Use the model influence × decision consequence framework. If you’re uncertain, default to the higher tier until the assessment is complete.
Validate proportionally. Low-risk tools need basic functional verification and user training documentation. High-risk tools need locked models, reference dataset testing, and human-interaction validation accounting for real-world verification capacity.
Establish a monitoring cadence. Define drift triggers, document revalidation criteria, and integrate AI model updates into your change control process. These need to exist before a drift event occurs.
Communicate limitations clearly. The principles require plain-language documentation of AI system limitations accessible to users and reviewers. Train your teams. Document what the tool does and does not do. Make that documentation retrievable.
AI can strengthen compliance. It can reduce risk. It can make maintenance teams faster, calibration programs more efficient, and quality documentation more reliable. The 10 principles released this January aren’t an obstacle to that outcome — they’re the framework that makes it defensible.
EMA and FDA are explicit: the goal is to allow AI to be “fully realized” while protecting information reliability for patient safety and regulatory excellence. The organizations positioned to benefit most are those treating AI the same way they treat any other validated system — with documented governance, proportional rigor, and ongoing oversight.
Start that work now.
Blue Mountain Quality Resources provides GMP-compliant enterprise asset management and CMMS solutions built to meet GxP requirements for life sciences manufacturers. For more on how we approach validated system governance, contact us.
